Exodus Point Capital Management, LP Adaptimmune Therapeutics PLC Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$1.06 - $2.41 $74,505 - $169,394	70,288 Added 23.43%	370,288 $398,000
Q2 2022 Aug 19, 2022	BUY	$1.33 - $2.28 $399,000 - $683,999	300,000 New	300,000 $510,000
Q4 2021 Feb 11, 2022	SELL	$3.5 - $5.68 $301,707 - $489,627	-86,202 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $296,534 - $549,106	86,202 New	86,202 $446,000
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $376,908 - $525,363	-76,920 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $185,252 - $426,079	46,313 Added 151.32%	76,920 $415,000
Q3 2020 Nov 16, 2020	BUY	$7.66 - $10.78 $234,449 - $329,943	30,607 New	30,607 $244,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $101M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.